上海康鹏科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 证券代码：688602 证券简称：康鹏科技 公告编号：2025-036 （一） 股东大会召开的时间：2025 年 5 月 13 日 （二） 股东大会召开的地点：上海市普陀区祁连山南路 2891 弄 200 号 1 幢一楼 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 78 | | --- | --- | | 普通股股东人数 | 78 | | 2、出席会议的股东所持有的表决权数量 | 279,027,823 | | 普通股股东所持有表决权数量 | 279,027,823 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 53.7237 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 53.723 ...

Group 1: Legal and Regulatory Developments - A U.S. federal judge ruled that Apple violated a previous court order, requiring the company to open its App Store to allow external payment methods, which could change the iOS payment landscape [2] - Apple has appealed the ruling, but developers within the iOS ecosystem can start directing consumers to third-party payment channels for at least two months before the appeal outcome [2] Group 2: Technology and Product Updates - Google launched the upgraded Gemini 2.5 Pro AI model, enhancing capabilities in coding and interactive web application development, available through Gemini API and Google’s Vertex AI [3] - Apple AI is expected to debut in the iOS 18.6 system in China, supported by Alibaba and Baidu, with Baidu's Wenxin Yiyan model as the core engine [3] - OpenAI announced a shift back to a Public Benefit Corporation model, maintaining nonprofit control over its operations, amidst criticism and legal challenges [3] Group 3: Market Strategies and Competition - Apple is changing its iPhone marketing strategy to release lower-end models in the first half of the year and high-end models in the second half, aiming to address competition in markets like China [4] - Tesla reported that over 95% of the parts for its Model 3 and refreshed Model Y are sourced from China, highlighting its reliance on local suppliers [4] Group 4: Corporate Actions and Partnerships - WeRide and Uber announced an expansion of their strategic partnership to deploy Robotaxi services in 15 new international cities over the next five years [6] - Pony.ai and Uber also reached a strategic partnership to integrate Pony.ai's Robotaxi services into the Uber platform, starting in the Middle East [7] Group 5: Industry Trends and Innovations - The global DRAM market saw a 42.5% year-on-year growth in Q1 2025, with SK Hynix overtaking Samsung to become the market leader with a 36.7% share [9] - Guoxin Technology successfully tested its quantum-resistant chip, AHC001, which is designed for high-security applications in finance, communication, and IoT [9]

Group 1 - US stock market experienced a decline with the Dow Jones down 0.95%, Nasdaq down 0.87%, and S&P 500 down 0.77% [1] - Popular Chinese concept stocks saw significant gains, with Xiaoma Zhixing up over 47%, Wenyan Zhixing up over 31%, and Bitdeer up over 6% [1] - Tesla faced challenges in Europe with double-digit declines in six major markets, including a two-year low in the UK and nearly a halving in Germany [8] Group 2 - The US trade deficit expanded to a record high of $140.5 billion in March [2] - The Trump administration is preparing to issue an executive order aimed at accelerating the deployment of nuclear reactors [4] - Huang Renxun stated that the Chinese AI chip market is expected to reach a scale of $50 billion [5] Group 3 - The European Union is considering countermeasures against the US, planning to impose tariffs on $100 billion worth of US goods if negotiations fail [9] - COMEX gold futures saw a rise of over 3%, with prices surpassing $3,400 per ounce [10] Group 4 - The Chinese government plans to implement a package of financial policies to stabilize the market and expectations [11][12] - The Ministry of Commerce announced that China has agreed to engage in talks with the US [12] - The first quarter GDP growth in China was reported at 5.4% year-on-year, with confidence in achieving a 5% growth target by 2025 [20] Group 5 - The quantum computing industry in China is advancing with the launch of a fourth-generation quantum computing measurement and control system [16][21] - The DRAM market is expected to grow significantly, with a 42.5% year-on-year increase to $26.729 billion in Q1 2025, driven by AI server demand and recovery in PC and mobile sectors [21] - Huawei is set to unveil its HarmonyOS PC, marking a significant development in domestic computer technology [22][23]

Group 1 - Ningde Times announced a share buyback plan with a total fund of 40 billion to 80 billion yuan, having repurchased 6.641 million shares, accounting for 0.1508% of the total share capital, with a total expenditure of 1.551 billion yuan [1] - Guoxin Technology successfully tested its quantum-resistant password chip AHC001, which is based on a domestic 28nm process and features low power consumption and high security, aimed at high-security applications [2] - Jingcheng Co. plans to introduce investors through a capital increase and share expansion for its subsidiary Tianhai Hydrogen Energy, with details yet to be determined [3] Group 2 - Weir Shares' shareholder plans to exchange up to 10 million shares for an open-ended index fund, representing 0.82% of the total share capital, aimed at optimizing asset allocation [4] - Zhejiang University Network New committed 33 million yuan to invest in a venture capital fund focusing on artificial intelligence and robotics, with a total target size of 100 million yuan [5] - Huayi Group intends to acquire 60% of San Aifu for 4.091 billion yuan to expand its business in fluorine fine chemicals, with funding sourced from its own or self-raised funds [6] Group 3 - Huina Technology's controlling shareholder is planning a change of control, leading to a temporary suspension of stock trading [7] - Tongyu Heavy Industry's actual controller will change from Zhuhai State-owned Assets Supervision and Administration Commission to Shandong State-owned Assets, following a share transfer agreement [8] - Kangxi Communication terminated its major asset restructuring plan and shifted to a strategic investment plan to acquire 35% of Shenzhen Chip Zhongxin Technology [9] Group 4 - Huafeng Measurement Control's shareholder plans to transfer 2.9% of its shares due to funding needs, with the transfer price set at a minimum of 70% of the average trading price over the previous 20 trading days [10] - Xiangyuan Cultural Tourism reported a 50.47% year-on-year increase in revenue during the May Day holiday [13] - Sairisi's April new energy vehicle sales increased by 12.99% year-on-year [13]

Investment Rating - The investment rating for Shanghai Chemspec (688602 CH) is not explicitly stated in the provided documents [1]. Core Insights - In 2024, the net profit attributable to the parent company was -0.50 billion yuan, a year-on-year decrease of 143.95%, with operating income of 675 million yuan, down 31.11% year-on-year [4][5]. - The geopolitical impact has deepened, leading to increased external uncertainties in international trade and weak overall market performance [4]. - The company expects a more optimistic outlook for 2025, with new materials actively developing metallocene co-catalyst projects and polyimide monomer projects, supported by large orders in the CDMO segment [5][6]. Summary by Sections Financial Performance - In 2024, the company achieved operating income of 675 million yuan, a year-on-year decrease of 31.11%, and a net profit attributable to the parent company of -0.50 billion yuan, a year-on-year decrease of 143.95% [4][5]. - The fourth quarter of 2024 saw operating income of 151 million yuan, down 18.32% year-on-year, and a net profit of -0.32 billion yuan, a year-on-year decrease of 1881.03% [4][5]. - For 2025 Q1, the company reported a net profit of 31 million yuan, a year-on-year increase of 59.73%, with operating income of 243 million yuan, up 44.27% year-on-year [5]. Product Segmentation - In 2024, the operating income from new materials was 358 million yuan, a year-on-year decrease of 6.03%, with a gross profit margin of 2.70%, down 7.90 percentage points [6]. - The CDMO business generated 295 million yuan in operating income, a year-on-year decrease of 48.29%, with a gross profit margin of 23.17%, down 16.06 percentage points [6]. Future Developments - The ETO production line expansion by Kangrun is expected to be implemented in 2026, with a 50,000-ton project currently under construction [7].

Investment Rating - The investment rating for Shanghai Chemspec (688602 CH) is not explicitly stated in the provided documents [1][2]. Core Insights - In 2024, the net profit attributable to the parent company was -0.50 billion yuan, a year-on-year decrease of 143.95%, with operating income of 675 million yuan, down 31.11% year-on-year [4][5]. - The geopolitical impact has deepened, leading to increased external uncertainties in international trade and weak overall market performance [4][5]. - The company expects a more optimistic outlook for 2025, with new materials actively developing metallocene co-catalyst projects and polyimide monomer projects, supported by large orders in the CDMO segment [5][6]. Financial Performance Summary - In 2024, the new materials segment generated operating income of 358 million yuan, a year-on-year decrease of 6.03%, with a gross profit margin of 2.70%, down 7.90 percentage points [6]. - The CDMO business reported operating income of 295 million yuan, a year-on-year decrease of 48.29%, with a gross profit margin of 23.17%, down 16.06 percentage points [6]. - In Q1 2025, the company achieved operating income of 243 million yuan, a year-on-year increase of 44.27%, and a net profit of 31 million yuan, up 59.73% year-on-year [5]. Production and Expansion Plans - The ETO production line expansion is expected to be implemented in 2026, with a 50,000-ton project currently under construction, aiming for production of less than 30,000 tons [7].

证券代码：688602 证券简称：康鹏科技 上海康鹏科技股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 会议资料目录 | 上海康鹏科技股份有限公司 | 2024 年年度股东大会会议须知 | | 2 | | --- | --- | --- | --- | | 上海康鹏科技股份有限公司 | 2024 年年度股东大会会议议程 | | 4 | | 上海康鹏科技股份有限公司 | 2024 年年度股东大会会议议案 | | 6 | | 议案一：关于 2024 | 年度董事会工作报告的议案 | | 6 | | 议案二：关于 2024 | 年度监事会工作报告的议案 | | 7 | | 议案三：关于 2024 | 年度独立董事述职报告的议案 | | 8 | | 议案四：关于 2024 年度财务决算及 | 2025 年度财务预算的议案 | | 9 | | 议案五：关于 2024 | 年年度报告及其摘要的议案 | | 13 | | 议案六：关于续聘 2025 | 年度会计师事务所的议案 | | 14 | | 议案七：关于 2024 | 年度利润分配方案的议案 | | 15 | | 议案八：关于修订《公司章程》、 ...

证券代码：688602 证券简称：康鹏科技 公告编号：2025-035 上海康鹏科技股份有限公司 关于新增募集资金专项账户并签订三方监管协议 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 2023 年 5 月 9 日经中国证券监督管理委员会《关于同意上海康鹏科技股份有 限公司首次公开发行股票注册的批复》(证监许可 [2023] 1007 号) 同意，上海康 鹏科技股份有限公司（以下简称"公司"）向社会公开发行人民币普通股 10,387.50 万股股份。本次发行每股价格为人民币 8.66 元，募集资金总额人民币 899,557,500.00 元，扣除发行费用后募集资金净额为人民币 810,659,607.10 元， 上述资金已全部到位。经毕马威华振会计师事务所 (特殊普通合伙) 审验并出具 毕马威华振验字第 2300834 号《验资报告》。公司依照规定对募集资金采取了专 户存储管理，开立了募集资金专户，与保荐机构中信建投证券股份有限公司（以 下简称"中信建投"、"保荐机构"）、募集资金专户监 ...

上海康鹏科技股份有限公司 证券代码：688602 证券简称：康鹏科技 公告编号：2025-034 召开地点：上海市普陀区祁连山南路 2891 弄 200 号 1 幢一楼会议室 （五） 网络投票的系统、起止日期和投票时间。 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 5 月 13 日 14 点 30 分 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 13 日 至2025 年 5 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年5月13日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 东 ...

Investment Rating - The report indicates a positive outlook for the weight loss drug sector within the pharmaceutical and biotechnology industry, suggesting potential acceleration in business development (BD) opportunities [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of -0.36% from April 14 to April 18, underperforming compared to the Wind All A index (0.39%) and the CSI 300 index (0.59). The market showed a preference for defensive sectors, with chemical preparations (0.62%), traditional Chinese medicine (0.6%), and offline pharmacies (0.19%) showing minor gains, while blood products (-4.39%), other biological products (-1.78%), and vaccines (-1.49%) saw significant pullbacks [2][7]. - The GLP-1 receptor agonists are expected to catalyze growth in the weight loss drug sector. Notably, Eli Lilly announced positive results from the Phase III ACHIEVE-1 study for its oral drug Orforglipron, which is set to expand the application of GLP-1 drugs. This class of drugs is becoming a focal point for multinational corporations (MNCs) in the metabolic disease space, with domestic companies poised to benefit from rapid innovation and lower R&D costs [2][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from April 14 to April 18 showed a decline of -0.36%, with the market favoring defensive stocks. The top gainers included Shuangcheng Pharmaceutical (56.4%), Kangpeng Technology (56.3%), and Lifang Pharmaceutical (47.1%), while the largest losers were *ST Jiyuan (-50.7%), Hasanlian (-19.1%), and Changyao Holdings (-18.5%) [7][10]. Industry News and Key Company Announcements - On April 17, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved positive results in its Phase III study, showing significant reductions in A1C levels and weight loss compared to placebo [12]. - Pfizer terminated the development of its GLP-1 small molecule receptor agonist Danuglipron due to potential liver damage in trial participants [12]. - The report highlights several companies making strides in the industry, including the approval of new indications for Merck's Gardasil 9 HPV vaccine and the progress of various clinical trials for innovative drugs [13][14].